

CURRICULUM VITAE

Omid Omidvar, M.D.

Collaborative Neuroscience Network, Inc.
2600 Redondo Avenue, Suite 500
Long Beach, CA 90806
(866) 787-4257

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Site Liaison
Tel. (866) 669-0234
Fax (208) 575-3169
Email: clinicaltrials@btheodore.com

AFFILIATIONS:

Collaborative Neuroscience Network, Inc.
12772 Valley View Street, Suite 3
Garden Grove, CA 92845

Collaborative Neuroscience Network, Inc.
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502

Ocean View Psychiatric Health Facility
2600 Redondo Avenue, Suite 500
Long Beach, CA 90806

Southland Neurologic Associates, Inc.
3791 Katella Avenue, Suite 106
Los Alamitos, CA 90720

Los Alamitos Medical Center
3751 Katella Ave
Los Alamitos, CA 90720

Long Beach Memorial Medical Center
2801 Atlantic Avenue
Long Beach, CA 90806

EDUCATION:

June 1994 Diplôme d'Etat de Docteur en Médecine, France

INTERNSHIPS AND RESIDENCIES:

1992-93 Internship in Internal Medicine and Emergency Medicine
University and Hospital Center of Rouen, France

1994-95 Internship in Internal Medicine
University of Nevada, Las Vegas, NV

1995-98 Resident in Neurology
Harbor-UCLA Medical Center, Torrance, CA

1996-98 Chief Resident in Neurology
Harbor-UCLA Medical Center, Torrance, CA

CERTIFICATION:

Board Certified in Neurology, March 2010

LICENSURE:

California Medical License: Number available on request

PROFESSIONAL EXPERIENCE:

Investigator, Collaborative Neuroscience Network, Inc. 2007 – Present

Private Practitioner, 1998 - Present
Southland Neurologic Associates, Los Alamitos, CA

Clinical Faculty, 1999-2008
Harbor-UCLA Medical Center, Torrance, CA

Vice Chairman of Department of Medicine, 2008-2009
Los Alamitos Medical Center, Los Alamitos, CA

Chairman of Pharmacy and Therapeutic Committee, 2006-2007
Los Alamitos Medical Center, Los Alamitos, CA

Assistant Clinical Professor of Neurology, 2003-2009
David Geffen UCLA school of Medicine, Los Angeles, CA

INVESTIGATOR EXPERIENCE:

Alzheimer's Disease • Diabetic Neuropathy • Epilepsy • Hypotension • Low Back Pain
Migraine • Neurogenic Orthostatic Hypotension • Parkinson's Disease • Phase I
Post-Herpetic Neuralgia • Primary Autonomic Failure Restless Legs Syndrome (RLS)

ADDITIONAL TREATMENT EXPERIENCE:

Chronic Pain • Fibromyalgia • Insomnia • Multiple Sclerosis • Stroke

CLINICAL TRIAL EXPERIENCE:

Phase I

A Phase I, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Effects of Multiple Doses of XXX on Cerebrospinal Fluid Biomarkers, Connectivity Magnetic Resonance Imaging, and Computerized Cognitive Tests in Subjects with Mild Alzheimer's Disease

A Phase I, parallel, single-dose, dose-escalation, placebo-controlled, randomized, subject- and investigator-blinded, inpatient/outpatient study in prodromal, mild, and moderate Alzheimer's disease (AD) patients to assess the safety, PK, PD, and immunogenicity of XXX. Five to six cohorts (6 patients on XXX and 2 on placebo per cohort) are planned with 1 period per cohort (12 weeks of follow up after dosing) to investigate doses from 0.1 up to 10 mg/kg

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multiple, Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of XXX in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

A Phase I, Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of XXX in Subjects With Mild to Moderate Alzheimer's disease

A Phase I, Open-Label, Randomized, Parallel Group, Crossover Study to Compare the Pharmacokinetics of XXX in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study of Safety and Tolerability of XXX in Adult Patients with Parkinson's Disease Who Are Receiving XXX Advanced Parkinson's Disease

A Phase I Study Investigating the Potential Interaction between XXX and Antipsychotic Treatments in Subjects with Schizophrenia or Schizoaffective Disorder

This is a Phase I, 2-part, open label, inpatient study to assess the safety and tolerability of multiple ascending doses of XXX in subjects with schizophrenia

CLINICAL TRIAL EXPERIENCE (continued):

Alzheimer's Disease

A Phase IIIb Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in XXX Phase III Clinical Studies XXX or Who Completed Studies XXX but did not Enroll in Study XXX

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Biomarker, Safety, and Pharmacokinetic Study of XXX Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer Disease

A Phase III, Open Label Extension of XXX Evaluating XXX in Patients with Alzheimer's Disease

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of XXX in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E ε4 Non-Carriers

A 2-Part, Randomized, Double Blind, Sequential, Multiple Ascending Dose, Placebo Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX in Elderly Subjects with and without Alzheimer's Disease

A 24 Week Open-Label Extension to Study XXX: A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type (ACTION)

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Prodromal Alzheimer's Disease

A Phase III, Multicenter, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in subjects with Alzheimer's Disease who Participated in Study XXX or XXX .

CLINICAL TRIAL EXPERIENCE (continued):

A Multi-center, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease

A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication

A Phase III Multi-center, Randomized, Placebo-Controlled, Double-Blind, Twelve-Month Safety and Efficacy Study Evaluating XXX in Patients with Mild-to-Moderate Alzheimer's Disease on XXX

A Randomized, Open-Label, Three-Period Cross-Over Study in Healthy Subjects to Compare the Pharmacokinetic Profiles of a 7-Day Application of the XXX Transdermal Patch-System to Three Different Skin Sites

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease

A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of XXX in Patients with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E 4 Non-Carriers AND A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of XXX in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Carriers

A Phase III, Multi-center, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in Subjects with Alzheimer's Disease Who Participated in Study XXX or in Study XXX

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

Epilepsy

A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXX Monotherapy in Subjects with Partial-onset Seizures

A Phase III, Multi-center, Open-Label Study Designed to Assess the Safety and Tolerability of Intravenously Administered XXX in Adult Subjects with Epilepsy. This Study will Include a 28 day Lead-in Period, a Confinement Period (up to 7 days and 6 nights) and a 28 day Follow-up Period

CLINICAL TRIAL EXPERIENCE (continued):

Efficacy and Safety of XXX as Adjunctive Therapy for Refractory Partial Seizures in a Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-centre Clinical Trial

A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXX, XXX, and XXX as Adjunctive Therapy in Subjects with Partial Onset Seizures

Conversion to Monotherapy for Adults with Epilepsy Experiencing Partial Seizures (with or without Secondary Generalization), A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXX Monotherapy in Subjects with Partial-onset Seizures

An International, Double-Blind, Randomized, Multi-center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of XXX in Subjects (≥ 16 to 75 years old) with Partial Onset Seizures with or without Secondary Generalization

A Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of XXX Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs and Long-Term Extension XXX Study for the XXX Double-Blind Monotherapy Study

Migraine

A Six Month Phase II/III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of XXX for Prevention of Menstrually Related Migraine in Female Patients with Episodic Migraine

A Study of the Chronic Intermittent Use of XXX, XXX, and XXX in the Acute Treatment of Migraine Attacks with or without Aura in Adults to Evaluate the Effect on Blood Pressure

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of XXX Versus XXX Containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Pain Phase of the Migraine

A Randomized, Double Blind, Placebo Controlled, Parallel Group Study of XXX in Adult Migraineurs

Pain

A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of XXX for Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized, Placebo-Controlled Trial of XXX Added to Nonsteroidal Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment

A Phase II, Multicenter, Randomized, Double-Blind, Placebo, Active Controlled Study Comparing the Analgesic Efficacy and Safety of XXX to Placebo in Subjects with Diabetic Neuropathic Pain

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Diabetic Painful Neuropathy and Small Fiber Neuropathy Associated with Impaired Glucose Tolerance Followed by a Double-Blind Safety Extension and an Open Label Safety Extension

An Open-label, Multi-center Trial to Assess the Long-term Safety and Efficacy Of XXX in Opioid-experienced Subjects with Chronic Noncancer Pain

A Phase II Randomized, Double Blind Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effect of XXX in Adult Patients with Chronic Low Back Pain

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of XXX in Patients with Osteoarthritis of the Knee

A Randomized, center, Double-Blind, Parallel-Group Trial with Controlled Adjustment of Dose Assessing the Analgesic Efficacy and Safety of a New Analgesic Compared with Placebo in Subjects with Painful Diabetic Peripheral Neuropathy

A Phase IIb Repeat Dosing Clinical Trial of XXX in Subjects with Moderately Severe Diabetic Neuropathy

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Proof-of-Concept Study To Evaluate The Efficacy Of Maximally Tolerated Doses of XXX vs. Placebo In Reducing The Pain Associated With Post-Herpetic Neuralgia

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Comparing the Analgesic Efficacy and the Safety of XXX (1 Mg, 2 Mg, And 4 Mg), XXX (60 Mg) and Placebo in Approximately 275 Subjects with Diabetic Neuropathic Pain

CLINICAL TRIAL EXPERIENCE (continued):

Parkinson's Disease

A Phase II, Randomized, Open-Label, Crossover Study to Compare XXX to an Immediate-Release Carbidopa/Levodopa Tablet in Patients with Advanced Parkinson's Disease with Motor Fluctuations

A 40-Week, Active-Controlled, Double-Blind, Double-Dummy Extension Study of XXX in Subjects With Moderate to Severe Parkinson's Disease

A Phase III, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXX in Subjects with Moderate to Severe Parkinson's Disease

A Phase II Efficacy, Safety and Pharmacokinetic Study of XXX and XXX in Parkinson's Disease Subjects with Motor Fluctuations

A Phase IIa - a Randomized, Double-Blind, Cross Over Study Comparing the Tolerability of Two Dose Regimens of XXX in Adult Patients with Parkinson's Disease who are Receiving A Study to Evaluate the Safety and Efficacy of XXX in Advanced Parkinson's Disease

A Placebo-controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Parkinson's Disease

An Open Label Extension Study of the Safety and Clinical Utility of XXX in Subjects with Parkinson's Disease (the "Study"), bearing protocol number XXX

A Randomized, Double-Blind, 2-Way Crossover Study to Compare XXX to Standard Carbidopa-Levodopa and Characterization of Multiple-Dose Pharmacokinetics and Pharmacodynamics of XXX in Levodopa-Experienced Parkinson's Disease Subjects with Motor Complications

A Multi-center, Double Blind, Parallel-Group Placebo and XXX Controlled Study to Explore the Efficacy, Tolerability and Safety of Different Doses and Titration Schedules of XXX Monotherapy in the Treatment of Patients with Early Stage Parkinson's Disease

A Study to Compare Pharmacokinetics and Pharmacodynamics of XXX to XXX

Other

A Phase III Outpatient Genentech Quintiles WA21092, WA21093 Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of XXX In Comparison To XXX In Patients With Relapsing Multiple Sclerosis.

CLINICAL TRIAL EXPERIENCE (continued):

A Multi-center, Open-Label Study to Assess the Long-Term Safety of XXX in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

A Fixed Dose Randomized, Double-Blind, 12-week Study of XXX Subjects with Moderate to Severe Idiopathic Restless Legs Syndrome

A Multi-center, Double-Blind, Randomized, Placebo-Group Induction Design Study to Assess the Clinical Effect of XXX in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency

A Fixed-dose, Randomized, 12-Week Placebo-Controlled, 52-week Comparator-Controlled, Double-Blind Study to Assess the Rates of Augmentation, Efficacy and Safety of XXX and XXX in Subjects with Moderate to Severe Idiopathic RLS

MEMBERSHIPS:

American Academy of Neurology 1996
California Medical Association

AWARDS:

Outstanding Teaching Attending, 1998-1999, St. Mary's Medical Center
Affiliated with UCLA School of Medicine Top Doctor's – Consumer's Checkbook 2004 and 2009
Resident Scholarship Award Recipient 1997

RESEARCH PROJECTS:

Study of Respiratory Centers and Functional MRI, under Professor R.M. Harper and Dr D. Gozal, Department of Neuroanatomy, Brain Research Institute, UCLA School of Medicine

ABSTRACTS AND PUBLICATIONS:

D. Gozal, O. Omidvar, K.A.T. Kirlew, G. M. Hathout, R. M. Hamilton, J. Zhang, R.B. Lufkin and R.M. Harper, Identification of human brain regions underlying responses to inspiratory loading with functional magnetic resonance imaging, *Proceedings of National Academy of Sciences USA*, Vol. 92 pp. 6607-6611, July 1995.

ABSTRACTS AND PUBLICATIONS (continued):

D. Gozal, O. Omidvar, K.A.T. Kirlew, G. M. Hathout, R. M. Hamilton, J. Zhang, R.B. Lufkin and R.M. Harper, Functional magnetic resonance imaging reveals brain regions mediating the response to resistive expiratory loads in humans, *Journal of Clinical Investigation*, Vol. 97 no. 1 pp. 47-53, Jan. 1996.

G. Aljadeff, D. Gozal, J. L. Carroll D. Rector, O. Omidvar, R. K. Harper, R.M. Harper, Ventral medullary surface responses to transient hypoxia and hyperoxia in the cat: Effect of carotid sinus denervation, Brain Research Institute; UCLA School of Medicine. Abstract presented at the 1994 annual meeting of the Society for Neuroscience.

THESIS:

Presented at the Faculté de Médecine de Rouen on June 17, 1994. This thesis was awarded among the highest qualifications of French rankings: **Félicitation des jurées, Mention très Honorables, Echange Internationale:**

Régions cérébrales participant à la réponse ventilatoire lors de l'application des charges resistives chez l'homme, études par L'IRM.

LANGUAGES:

English, French, Farsi and some Spanish.